Abstract
Many effective anti-glaucoma drugs available for the treatment of ocular hypertension and open angle glaucoma are associated with rapid and extensive precorneal loss caused by the drainage and high tear fluid turnover. The present study involved design of mucoadhesive nanoparticulate carrier system containing betaxolol hydrochloride for ocular delivery to improve its corneal permeability and precorneal residence time. Nanoparticles were prepared by spontaneous emulsification method and had a particle size of 168-260nm with zeta potential of 25.2-26.4 mV. The in vitro release studies in simulated tear fluid exhibited biphasic release pattern with an initial burst followed by sustained release upto 12 h. The sterility tests confirmed that formulation was free from viable microorganisms and suitable for ocular delivery. The ocular tolerance of nanoparticles was evaluated using Hen Egg-Chorion Allantoic Membrane (HE-CAM) method and was found to be non-irritant. Stability studies of nanoparticles revealed that there was no significant change in particle size and drug content after storage at 25±2°C/60±5% RH over a period of 3 months. In vivo pharmacodynamic studies were carried out in dexamethasone induced glaucoma model in rabbits. The developed nanoparticles showed significant decrease in intraocular pressure (IOP) compared to marketed formulation. Optimized formulation of BN3 showed gradual reduction of IOP reaching peak value of 9.9±0.5mm Hg, equivalent to 36.39±1.84% reduction in IOP compared to control at the end of 5 h which was significant (p < 0.05) compared to marketed formulation. Thus, our studies demonstrate that developed nanoparticles offer a promising delivery system for the management of glaucoma.
Keywords: Betaxolol, glaucoma, chitosan, nanoparticles, ocular delivery.
Current Drug Delivery
Title:Betaxolol Hydrochloride Loaded Chitosan Nanoparticles for Ocular Delivery and their Anti-glaucoma Efficacy
Volume: 10 Issue: 5
Author(s): Kunal Jain, R. Suresh Kumar, Sumeet Sood and G. Dhyanandhan
Affiliation:
Keywords: Betaxolol, glaucoma, chitosan, nanoparticles, ocular delivery.
Abstract: Many effective anti-glaucoma drugs available for the treatment of ocular hypertension and open angle glaucoma are associated with rapid and extensive precorneal loss caused by the drainage and high tear fluid turnover. The present study involved design of mucoadhesive nanoparticulate carrier system containing betaxolol hydrochloride for ocular delivery to improve its corneal permeability and precorneal residence time. Nanoparticles were prepared by spontaneous emulsification method and had a particle size of 168-260nm with zeta potential of 25.2-26.4 mV. The in vitro release studies in simulated tear fluid exhibited biphasic release pattern with an initial burst followed by sustained release upto 12 h. The sterility tests confirmed that formulation was free from viable microorganisms and suitable for ocular delivery. The ocular tolerance of nanoparticles was evaluated using Hen Egg-Chorion Allantoic Membrane (HE-CAM) method and was found to be non-irritant. Stability studies of nanoparticles revealed that there was no significant change in particle size and drug content after storage at 25±2°C/60±5% RH over a period of 3 months. In vivo pharmacodynamic studies were carried out in dexamethasone induced glaucoma model in rabbits. The developed nanoparticles showed significant decrease in intraocular pressure (IOP) compared to marketed formulation. Optimized formulation of BN3 showed gradual reduction of IOP reaching peak value of 9.9±0.5mm Hg, equivalent to 36.39±1.84% reduction in IOP compared to control at the end of 5 h which was significant (p < 0.05) compared to marketed formulation. Thus, our studies demonstrate that developed nanoparticles offer a promising delivery system for the management of glaucoma.
Export Options
About this article
Cite this article as:
Jain Kunal, Kumar Suresh R., Sood Sumeet and Dhyanandhan G., Betaxolol Hydrochloride Loaded Chitosan Nanoparticles for Ocular Delivery and their Anti-glaucoma Efficacy, Current Drug Delivery 2013; 10 (5) . https://dx.doi.org/10.2174/1567201811310050001
DOI https://dx.doi.org/10.2174/1567201811310050001 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthesis and Biological Study of 3-Butyl-1-(2,6-dichlorophenyl)-1H-[1,2,4]triazol- 5(4H)-one Derivatives as Anti-hypertension Drugs
Letters in Drug Design & Discovery The Proteomic Approach in the Development of Prognostic Biomarkers in Atherothrombosis
Recent Patents on Cardiovascular Drug Discovery Protein Kinases as Drug Targets in Human and Animal Diseases
Current Enzyme Inhibition Novel Concepts in the Pathogenesis and Management of Pediatric Hypertension
Current Pediatric Reviews Hydrogen Peroxide Produced by Mitochondrial Monoamine Oxidase Catalysis: Biological Implications
Current Pharmaceutical Design Intestinal Permeability in Non-alcoholic Fatty LIVER Disease: The Gut-liver Axis
Reviews on Recent Clinical Trials An Overview of Hepatoprotective Effects of Thymoquinone
Recent Patents on Food, Nutrition & Agriculture Meet the Editorial Board
Current Pharmaceutical Design Magnesium and Aging
Current Pharmaceutical Design Gender Specific Aspects of Cell Death in the Cardiovascular System
Current Pharmaceutical Design Cellular Senescence in Cardiovascular Diseases: Potential Age-Related Mechanisms and Implications for Treatment
Current Pharmaceutical Design Angiogenesis and Microvasculature in the Female Reproductive Organs: Physiological and Pathological Implications
Current Pharmaceutical Design Oxidative Stress as a Key Signaling Pathway in Placental Angiogenesis Changes in Preeclampsia: Updates in Pathogenesis, Novel Biomarkers and Therapeutics
Current Pharmacogenomics and Personalized Medicine Lactic Acidosis, Hypotension, and Sensorineural Hearing Loss Following Intentional Metformin Overdose
Current Drug Safety Mucoadhesive Microspheres Containing Anti-Hypertensive Agent: Formulation and Characterization
Current Drug Delivery Editorial [Hot Topic: Clinical Management and Treatment of Hypertension, Its Pathophysiology and the Clinical Use of Antihypertensive Drugs (Executive Editor: Gregory Y.H. Lip)]
Current Pharmaceutical Design Haptoglobin Phenotype May Alter Endothelial Progenitor Cell Cluster Formation in Cerebral Small Vessel Disease
Current Neurovascular Research L-Arginine Transport and Nitric Oxide Production in Kinin Receptor B1-/- Endothelial Cells.
Protein & Peptide Letters In Vitro Inhibition of Key Enzymes Related to Diabetes by the Aqueous Extracts of Some Fruits of West Bengal, India
Current Nutrition & Food Science Effects of Renin-Angiotensin-Aldosterone System Blockade on Diabetic Patients
Current Enzyme Inhibition